These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 911471)

  • 1. [Behavior of phosphohexose isomerase activity (PHI) in the serum, pleural effusions, and ascitic fluids of subjects with malignant hematologic diseases and tumors].
    Valguarnera G; Trippiedi MA
    Boll Soc Ital Biol Sper; 1977 Jan; 53(1-2):15-9. PubMed ID: 911471
    [No Abstract]   [Full Text] [Related]  

  • 2. [Phosphohexose isomerase in cyst fluids and effusions as a complement to cytological diagnosis].
    Geier G; Müller B
    Fortschr Med; 1983 Dec; 101(46):2146-50. PubMed ID: 6662466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on glycolytic enzymes in relation to cancer. Part IV: Sera and effusion activities of phosphohexose isomerase, aldolase and lactic dehydrogenase in malignant and benign conditions.
    Damle SR; Talavdekar RV
    Indian J Cancer; 1974 Sep; 11(3):280-4. PubMed ID: 4442917
    [No Abstract]   [Full Text] [Related]  

  • 4. The lactate dehydrogenases in malignant and non-malignant diseases.
    Oladipo OO; Ajala MO; Afonja OA
    Niger Postgrad Med J; 2002 Mar; 9(1):1-6. PubMed ID: 11932752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive effusion cytology as the initial presentation of malignancy.
    Monte SA; Ehya H; Lang WR
    Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of diamine oxidase (DAO) in serous effusions of neoplastic and non neoplastic origin (author's transl)].
    Rossi L; Bombardieri G; Bevilacqua E; Innocenti P
    Quad Sclavo Diagn; 1980 Dec; 16(4):412-8. PubMed ID: 6787656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of the determination of serum phosphohexose isomerase in malignant neoplasms].
    Bruno GF; Failla G; Foti E; Marchese V
    Minerva Med; 1978 Mar; 69(12):749-56. PubMed ID: 643216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of hexokinase activity in body fluids in malignant neoplasms].
    Neĭfakh SA; Grekh IF; Maleeva ZV; Mikhaĭlov VV; Monakhov NK
    Vopr Onkol; 1968; 14(1):3-9. PubMed ID: 5690749
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphohexose isomerase activity as a tumor marker in hepatoma bearing rats (Yoshida A.H. 130).
    Neri B; Pieri A; Ciapini A; Pucci M
    Anticancer Res; 1982; 2(5):287-9. PubMed ID: 7165285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The activity of isocitra dehydrogenase and of phosphohexose isomerase in the serum of patientwith malignant tumors of the mouth cavity].
    Casella M
    Arch Stomatol (Napoli); 1968; 9(4):359-63. PubMed ID: 5267533
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative evaluation of lactate dehydrogenase and glucose-6-phosphate isomerase activity in patients with neoplasms].
    Lanfranco G; Bossi E; Bonelli G; Gino G; Falda M; Pellati M
    Cancro; 1974; 27(6):305-12. PubMed ID: 4469878
    [No Abstract]   [Full Text] [Related]  

  • 12. Telomerase activity in benign and malignant cytologic fluids.
    Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
    Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum phosphohexose isomerase in cancer.
    Rao YN; Chakravorty M; Khanna NN
    Indian J Cancer; 1976 Dec; 13(4):361-6. PubMed ID: 1022683
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of protease inhibition by ascitic and pleural fluids: comparative determinations of alpha-1-antitrypsin, alpha-2-macroglobulin and protease inhibition capacity].
    Bieth J; Miesch F; Métais P
    Ann Biol Clin (Paris); 1971; 29(1):51-8. PubMed ID: 5579075
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnostic utility of adenosine deaminase (ADA) activity in pleural fluid and serum of tuberculous and non-tuberculous respiratory disease patients.
    Lamsal M; Gautam N; Bhatta N; Majhi S; Baral N; Bhattacharya SK
    Southeast Asian J Trop Med Public Health; 2007 Mar; 38(2):363-9. PubMed ID: 17539288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H; Rona G; Hutter C; Bayer PM; Kummer F
    Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between pleural fluid pH, PCO2 to pleural fluid PO2, amylase, protein, glucose and white cells in tuberculous and malignant effusions.
    Limthongkul S; Charoenlap P; Nuchprayoon C; Songkhla YN
    J Med Assoc Thai; 1990 Aug; 73(8):429-32. PubMed ID: 1702135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuron-specific enolase in pleural effusions of various etiologies].
    Plavec G; Lazarov A; Dangubić V; Odavić M
    Plucne Bolesti; 1990; 42(1-2):88-91. PubMed ID: 2217645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value and limitations of the use of enzymatic diagnosis in malignant neoplasms. LDH zymograms, quantitative determination of GOT, GPT, LDH and MDH in blood and pleuro-abdominal effusion fluids].
    Emanuelli G; Cagetti M; Congiu P; Verzetti G; Montagnani M
    Quad Sclavo Diagn; 1972 Dec; 8(4):980-93. PubMed ID: 4668741
    [No Abstract]   [Full Text] [Related]  

  • 20. The metabolic behaviour of the cellular populations in the pleural or peritoneal effusions from patients with malignant diseases.
    Mihăilescu E; Micu D; Cheţa N; Chiriloiu C; Georgescu M; Vilău C
    Med Interne; 1986; 24(3):227-33. PubMed ID: 2430328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.